New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTOREX, ARNA, VVUSVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
14:30 EDTVVUSAdrianus van Herk reports 5.0% passive stake in VIVUS
Subscribe for More Information
April 29, 2015
08:22 EDTARNAArena Pharmaceuticals' pain treatment candidate shows positive Phase 1 results
Arena Pharmaceuticals announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 receptor currently in development for the treatment of pain and potentially fibrotic diseases. The Phase 1 clinical trial showed that APD371 was well tolerated at drug levels greatly exceeding those anticipated as needed for activating the CB2 receptor.
April 28, 2015
07:01 EDTVVUSVIVUS announces discount program through Sam's Club for Qsymia
Subscribe for More Information
April 22, 2015
07:37 EDTOREXOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 21, 2015
16:32 EDTVVUSVIVUS granted patents covering Qsymia compositions and methods
Subscribe for More Information
14:02 EDTOREXParagraph IV patent challenges submitted to FDA for Orexigen's Contrave
An Abbreviated New Drug Application, or ANDA, has been received by the Office of Generic Drugs containing a "Paragraph IV" patent certification for Contrave, the weight loss drug whose patent is owned by Orexigen Therapeutics, according to an FDA notice. The date on which the first substantially complete generic drug application was submitted to the Agency for Contrave was March 12, according to the posting. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use